Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Mallinckrodt Plc (NYSE:MNK)

83.06
Delayed Data
As of Aug 23
 +1.58 / +1.94%
Today’s Change
50.90
Today|||52-Week Range
90.64
+11.30%
Year-to-Date
Swiss Generics Manufacturer Has Strong 1st Half of Year
Aug 22 / GuruFocus News - Paid Partner Content
Mallinckrodt (MNK) to Buy Stratatech for Undisclosed Value
Aug 12 / Zacks.com - Paid Partner Content
Healthcare Growth Stocks in the S&P 500: Part 2
Aug 12 / GuruFocus News - Paid Partner Content
 

Today’s Trading

Previous close81.48
Today’s open82.28
Day’s range82.01 - 83.45
Volume1,443,848
Average volume (3 months)1,821,502
Market cap$8.8B
Dividend yield--
Data as of 4:02pm ET, 08/23/2016

Growth & Valuation

Earnings growth (last year)--
Earnings growth (this year)+16.35%
Earnings growth (next 5 years)+10.34%
Revenue growth (last year)+31.75%
P/E ratio18.1
Price/Sales2.40
Price/Book1.78

Competitors

 Today’s
change
Today’s
% change
JAZZJazz Pharmaceuticals...-0.78-0.58%
RDYDr.Reddy's Laborator...+0.44+0.98%
VRXValeant Pharmaceutic...-0.07-0.22%
ALKSAlkermes Plc+1.15+2.54%
Data as of 4:02pm ET, 08/23/2016

Financials

Next reporting dateNovember 16, 2016
EPS forecast (this quarter)$2.26
Annual revenue (last year)$3.3B
Annual profit (last year)$322.1M
Net profit margin9.13%

Profile

Sector
Health Technology
Industry
Pharmaceuticals: Other
President, Chief Executive Officer &
Director
Mark C. Trudeau
Senior Vice President-
Global Operations
Frank Scholz
Corporate headquarters
Chesterfield, Derbyshire

Forecasts

Partner Offers

Search for Jobs